StockNews.AI
XLO
StockNews.AI
1 min

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

1. Xilio will present clinical data at SITC Annual Meeting in November 2025. 2. Key presentations include vilastobart and efarindodekin alfa data. 3. The company focuses on tumor-activated therapies with potentially reduced side effects. 4. Clinical advancements may enhance efficacy for cancer patients. 5. Future data could impact investor sentiment and market value significantly.

8m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentations may reveal promising clinical data, akin to successes in prior oncology conferences that often boost stocks of biotech firms. For instance, companies like Mirati Therapeutics saw price increases after positive trial announcements at similar events.

How important is it?

The article highlights imminent presentations that could significantly impact stock performance, attracting investor attention and potential stock movement. The focus on promising therapies may boost overall investor interest in the biotech landscape.

Why Short Term?

The presentations are imminent (November 2025), likely resulting in immediate market reactions to clinical data. Investors often react swiftly to stock movement following in-conference data reveals.

Related Companies

MRTXCLDXKURE
October 03, 2025 09:00 ET  | Source: Xilio Therapeutics, Inc. WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced multiple upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 6-9, 2025 at the Gaylord National Convention Center in National Harbor, Maryland. Xilio plans to present clinical data for vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, and efarindodekin alfa (XTX301), a tumor-activated IL-12, and plans to present preclinical data highlighting the company’s masked T cell engager programs. Poster presentation details, as follows: Title: ctDNA as a Potential Surrogate Biomarker for Response to Combination Vilastobart and Atezolizumab in Heavily Pretreated Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)Abstract Number: 541Presentation Date: Friday, Nov. 7, 2025Poster Hall Hours: 9:00 a.m.-7:00 p.m. ESTLocation: Gaylord Exhibit Halls A & B1 Title: XTX301, a Tumor-Activated Interleukin-12 (IL-12), Demonstrated IL-12 Pharmacology in Patients with Advanced Solid Tumors: Pharmacodynamic Data from First-in-Human Phase 1 StudyAbstract Number: 567Presentation Date: Friday, Nov. 7, 2025Poster Hall Hours: 9:00 a.m.-7:00 p.m. ESTLocation: Gaylord Exhibit Halls A & B1 Title: Masked T Cell Engagers Designed to Drive Potent Synthetic Anti-Tumor Immunity with Favorable TolerabilityAbstract Number: 972Presentation Date: Saturday, Nov. 8, 2025Poster Hall Hours: 9:00 a.m.-8:40 p.m. ESTLocation: Gaylord Exhibit Halls A & B1 About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans to present data related to Xilio’s clinical programs for vilastobart and efarindodekin alfa and preclinical programs for masked T cell engagers; and Xilio’s strategy, goals and anticipated financial performance, milestones, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks related to general market conditions and geopolitical uncertainties; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio’s ability to advance multiple early stage masked T cell engager programs; initial, preliminary or interim preclinical or clinical data or results may not be replicated in or predictive of future preclinical or clinical data or results; Xilio’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio’s product candidates may not support further development of such product candidates; actions of regulatory agencies may affect the initiation, timing and progress of current or future clinical trials; Xilio’s ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio’s need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules; the impact of international trade policies on Xilio’s business, including U.S. and China trade policies; and Xilio’s ability to maintain its collaboration or partnership agreements with AbbVie, Gilead and Roche. These and other risks and uncertainties are described in greater detail in the sections entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s filings with the U.S. Securities and Exchange Commission (“SEC”), including Xilio’s most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. TECENTRIQ is a registered trademark of Genentech USA, Inc., a member of the Roche Group. Investor Contact  investors@xiliotx.com Media Contact  Josie Butler, 1ABjosie@1abmedia.com

Related News